103.36
15.93 (18.22%)
| Previous Close | 87.43 |
| Open | 90.23 |
| Volume | 2,076,149 |
| Avg. Volume (3M) | 657,450 |
| Market Cap | 6,566,026,752 |
| Price / Sales | 12.97 |
| Price / Book | 18.39 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | -29.48% |
| Operating Margin (TTM) | -38.21% |
| Diluted EPS (TTM) | -2.09 |
| Quarterly Revenue Growth (YOY) | 126.60% |
| Total Debt/Equity (MRQ) | 233.98% |
| Current Ratio (MRQ) | 3.32 |
| Operating Cash Flow (TTM) | -242.15 M |
| Levered Free Cash Flow (TTM) | -101.52 M |
| Return on Assets (TTM) | -14.97% |
| Return on Equity (TTM) | -49.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Blueprint Medicines Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.89% |
| % Held by Institutions | 104.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lord, Abbett & Co. Llc | 30 Sep 2024 | 1,178,190 |
| Pictet Asset Management Holding Sa | 30 Sep 2024 | 1,166,507 |
| Polar Capital Holdings Plc | 30 Sep 2024 | 877,005 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 151.00 (Wells Fargo, 46.09%) | Buy |
| Median | 130.50 (26.26%) | |
| Low | 88.00 (UBS, -14.86%) | Hold |
| Average | 128.00 (23.84%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 92.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 135.00 (30.61%) | Buy | 103.36 |
| 15 Nov 2024 | 135.00 (30.61%) | Buy | 88.69 | |
| Wedbush | 13 Jan 2025 | 124.00 (19.97%) | Buy | 103.36 |
| Stephens & Co. | 02 Jan 2025 | 140.00 (35.45%) | Buy | 87.20 |
| JMP Securities | 09 Dec 2024 | 125.00 (20.94%) | Buy | 94.57 |
| 18 Nov 2024 | 125.00 (20.94%) | Buy | 90.18 | |
| HC Wainwright & Co. | 15 Nov 2024 | 135.00 (30.61%) | Buy | 88.69 |
| 31 Oct 2024 | 135.00 (30.61%) | Buy | 87.51 | |
| JP Morgan | 14 Nov 2024 | 126.00 (21.90%) | Buy | 95.65 |
| Wells Fargo | 31 Oct 2024 | 151.00 (46.09%) | Buy | 87.51 |
| UBS | 24 Oct 2024 | 88.00 (-14.86%) | Hold | 83.09 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2025 | Announcement | Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth |
| 18 Dec 2024 | Announcement | Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 07 Dec 2024 | Announcement | Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting |
| 30 Oct 2024 | Announcement | Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance |
| 16 Oct 2024 | Announcement | Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |